Press Releases

 
Press Releases
  Date Title View
Nov 11, 2014
RADNOR, Pa., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2014 Stifel Healthcare Conference on Tuesd...
Sep 25, 2014
NEW HAVEN, Conn., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Edward F. Smith, Vice President and Chief Financial Officer of Marinus will present at the 21st Annual BioCentury Newsmakers Conf...
Sep 2, 2014
NEW HAVEN, Conn., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional...
Aug 25, 2014
NEW HAVEN, Conn., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that in celebration of its recently completed initial public offering and NASDAQ listing it will ring the opening bell at the NASDAQ Ma...
Aug 12, 2014
NEW HAVEN, Conn., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly owned subsidiary of Ligand Pharmaceutical Incorporated...
Jul 31, 2014
NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock at a public offering price of $8.00 per share, befor...
Jan 9, 2014
NEW HAVEN, CT -- (Marketwired) -- 01/09/14 -- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the election of two life science veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to its board of directors and the appointment of Edward F. Sm...
Jan 7, 2013
BRANFORD, Conn., Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RM...
Apr 13, 2011
NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department ...
Apr 7, 2011
NEW HAVEN, Conn., April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Numbe...
FirstPrevious
...
7
NextLast
= add release to Briefcase